Bouchi R, Kondo T, Ohta Y, et al. A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes. Diabetol Int. 2022;14(1):1–14.

Article  PubMed  PubMed Central  Google Scholar 

Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66(Suppl 1):S37–43.

Article  CAS  PubMed  Google Scholar 

Okamoto K, Iwasaki N, Nishimura C, et al. Identification of KCNJ15 as a susceptibility gene in Asian patients with type 2 diabetes mellitus. Am J Hum Genet. 2010;86(1):54–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36(6):1789–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kohro T, Yamazaki T, Sato H, et al. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54(2):93–7.

Article  PubMed  Google Scholar 

Bouchi R, Sugiyama T, Goto A, et al. Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig. 2022;13(2):280–91.

Article  CAS  PubMed  Google Scholar 

Koto R, Nakajima A, Miwa T, Sugimoto K. Multimorbidity, polypharmacy, severe hypoglycemia, and glycemic control in patients using glucose-lowering drugs for type 2 diabetes: a retrospective cohort study using health insurance claims in Japan. Diabetes Ther. 2023;14(7):1175–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rhee MK, Slocum W, Ziemer DC, et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31(2):240–50.

Article  PubMed  Google Scholar 

Nishimura R, Kato H, Kisanuki K, et al. Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. BMJ Open. 2019;9(3): e025806.

Article  PubMed  PubMed Central  Google Scholar 

Ito H, Ando S, Tsugami E, et al. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:41–8.

Article  CAS  PubMed  Google Scholar 

Tosaki T, Kamiya H, Yamamoto Y, et al. Efficacy and patient satisfaction of the weekly DPP-4 inhibitors trelagliptin and omarigliptin in 80 Japanese patients with type 2 diabetes. Intern Med. 2017;56(19):2563–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meguro S, Matsui S, Itoh H. Treatment preference for weekly versus daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: outcomes from the TRINITY trial. Curr Med Res Opin. 2019;35(12):2071–8.

Article  CAS  PubMed  Google Scholar 

Suzuki K, Hasegawa K, Watanabe M. Efficacy and patient satisfaction of dipeptidyl peptidase-4 inhibitor after switching from once-daily DPP-4 inhibitor to once-weekly regimen. J Clin Med Res. 2018;10(8):641–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oh A, Kisanuki K, Nishigaki N, et al. Comparison of persistence and adherence between DPP-4 inhibitor administration frequencies in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study. Curr Med Res Opin. 2020;36(3):387–95.

Article  CAS  PubMed  Google Scholar 

Ministry of Health, Labour and Welfare. An outline of the Japanese medical system. https://www.mhlw.go.jp/english/policy/health-medical/health-insurance/index.html. Accessed 31 May 2023.

Okada A, Yasunaga H. Prevalence of noncommunicable diseases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people. JMA J. 2022;5(2):190–8.

PubMed  PubMed Central  Google Scholar 

Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.

Article  PubMed  Google Scholar 

Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.

Article  PubMed  Google Scholar 

Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25(9):2303–10.

Article  PubMed  Google Scholar 

Baumgartner PC, Haynes RB, Hersberger KE, Arnet I. A systematic review of medication adherence thresholds dependent of clinical outcomes. Front Pharmacol. 2018;9:1290.

Article  PubMed  PubMed Central  Google Scholar 

Umemura S, Arima H, Arima S, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235–481.

Article  PubMed  Google Scholar 

Kinoshita M, Yokote K, Arai H, et al. Committee for epidemiology and clinical management of atherosclerosis. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018;25(9):846–84.

Article  PubMed  PubMed Central  Google Scholar 

Tunceli K, Zhao C, Davies MJ, et al. Factors associated with adherence to oral antihyperglycemic monotherapy in patients with type 2 diabetes. Patient Prefer Adherence. 2015;9:191–7.

PubMed  PubMed Central  Google Scholar 

Kurtyka K, Nishikino R, Ito C, Brodovicz K, Chen Y, Tunceli K. Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan. J Diabetes Investig. 2016;7(5):737–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moreno JA, Gimeno MA, Poblador PB, et al. Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. Med Clin (Barc). 2019;153(1):1–5.

Google Scholar 

Tsukube S, Kadowaki T, Odawara M. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan. Diabetol Int. 2016;7(3):299–307.

Article  PubMed  PubMed Central  Google Scholar 

Hauber AB, Tunceli K, Yang JC, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther. 2015;6(1):75–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sen R, Shields AL, Atsuda K. Patient preference for once-weekly dosing in type 2 diabetes mellitus in Japan. J Health Econ Outcomes Res. 2016;4(1):55–66.

Article  PubMed  PubMed Central  Google Scholar